ClinicalTrials.gg
CompletedNCT03037398CLOVERUpdated Oct 5, 2026Results posted

Closed Loop Programming Evaluation Using External Responses for Deep Brain Stimulation

An interventional study of Vercise Deep Brain Stimulation System in Parkinson Disease, sponsored by Boston Scientific Corporation. Completed at 3 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Boston Scientific Corporation · Not applicable, Interventional, and Treatment

How we know

Updated Oct 5, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Parkinson Disease by Boston Scientific Corporation — 3 open to participants now, 3 under way, none of them phase 3. Parkinson Disease · Boston Scientific Corporation.

Started
2017
the only one that year
No phase
6 of 10
none open now
Registered
6th of 10
by date

Among the 10 studies in Parkinson Disease by Boston Scientific Corporation, this one is the only one that started in 2017, is one of 6 with no phase, and was the 6th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

3 of the 10 studies in Parkinson Disease by Boston Scientific Corporation are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Parkinson Disease by Boston Scientific Corporation, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the performance of novel DBS programming methods compared to traditional programming methods.

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Implanted bilaterally in STN or GPi with a Vercise™ DBS system for Parkinson's disease, including directional leads, for at least four months and programming optimized according to standard of care with no changes to electrode configuration of primary settings for at least four weeks.
  • Able to understand the study requirements and the treatment procedures and provides written before any study-specific tests or procedures are performed.
  • Be at least 18 years of age.
  • Device must have been implanted on label or must be on label by the time the subject gets enrolled.

Key Exclusion Criteria:

  • Any significant psychiatric problems, including unrelated depression as determined by the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Novel Programming then Standard of Care (SOC) programming Arm

    Programming completed by a novel method first followed by Standard of care programming.

    Device: Vercise Deep Brain Stimulation System

  • Experimental
    Standard of Care Programming then Novel programming Arm

    Programming completed as Standard of care followed by Novel programming.

    Device: Vercise Deep Brain Stimulation System

Interventions

  • DeviceVercise Deep Brain Stimulation System
06

What researchers measure

Primary outcomes

  1. Change in Motor Function

    Mean change in Unified Parkinson's Disease Rating (UPDRS) Part III scores from Baseline meds off/stim off condition to Standard of care AND novel programming in meds off/stim on condition after randomization. Range 0 - 108. Higher scores indicate worse function.

    Time frame: Programming visit Day 1 after Randomization

07

Results

Posted Oct 5, 2026

Participant flow

Participant flow — Overall Study
MilestoneStandard of Care - Novel Algorithm SequenceNovel Algorithm - Standard of Care Sequence
Started3435
Completed3435
Not completed00

Outcome measures

PrimaryChange in Motor Function

Mean change in Unified Parkinson's Disease Rating (UPDRS) Part III scores from Baseline meds off/stim off condition to Standard of care AND novel programming in meds off/stim on condition after randomization. Range 0 - 108. Higher scores indicate worse function.

Time frame:
Programming visit Day 1 after Randomization
Reported as:
Mean · Score on a scale
Change in Motor Function
Score on a scaleStandard of Care - Novel Algorithm SequenceNovel Algorithm - SOC Sequence
Standard of Care vs Baseline Total UPDRS III Score Changes13.8 ± 10.716.5 ± 8.7
Novel algorithm vs Baseline Total UPDRS III Score Changes15.7 ± 8.615.9 ± 7.8

Adverse events

Collected over Randomized subjects through the Programming visit Day 1. An average of 4-8 weeks for all subjects to complete study activities through the Programming visit.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Standard of Care Programming0/69 (0%)0/69 (0%)2/69 (2.9%)
Novel Algorithm Programming0/69 (0%)0/69 (0%)0/69 (0%)
Most frequent other events
Most frequent other events
EventStandard of Care ProgrammingNovel Algorithm Programming
Parkinson's DiseaseNervous system disorders2/690/69

Baseline characteristics

Half of the participants were assigned to this arm.

Age, Continuous
Age, Continuous(Years)Standard of Care - Novel Algorithm SequenceNovel Algorithm - Standard of Care SequenceTotal
Mean60.9 ± 6.560.9 ± 7.960.9 ± 7.2
Sex: Female, Male
Sex: Female, Male(Participants)Standard of Care - Novel Algorithm SequenceNovel Algorithm - Standard of Care SequenceTotal
Female101121
Male242448
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Standard of Care - Novel Algorithm SequenceNovel Algorithm - Standard of Care SequenceTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)Standard of Care - Novel Algorithm SequenceNovel Algorithm - Standard of Care SequenceTotal
Germany343569
UPDRS-III score (meds off/stim off condition)
UPDRS-III score (meds off/stim off condition)(Units on a scale)Standard of Care - Novel Algorithm SequenceNovel Algorithm - Standard of Care SequenceTotal
Mean37.2 ± 13.135.7 ± 8.836.4 ± 11
08

Study locations

3 sites
  • University Berlin, Charite Virchow Standort, Wedding
    Berlin, Germany
  • Universitaetsklinik Eppendorf
    Hamburg, Germany
  • Universitätsklinikum Campus Kiel
    Kiel, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Apr 2025, 98 months.

Results were first posted in Oct 2026, 1 year 6 months after primary completion.

Of 76 industry-sponsored interventional studies with no phase under Parkinson Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's 98 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2017
First posted
Jan 31, 2017
StartActual
Jan 11, 2017
Primary completionActual
Apr 2, 2025
CompletionActual
Apr 2, 2025
Results first posted
Oct 5, 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 5, 2026
Enrollment
72→69
Oct 5, 2026
Interventions
Arm changed Standard of Care Arm→Standard of Care Programming then Novel programming Arm; Novel Arm→Novel Programming then Standard of Care (SOC) programming Arm
Oct 5, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Difference in time to program between the two arms at Programming VisitNow Change in Motor FunctionTime frame: at least four months post implant → Programming visit Day 1 after Randomization
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Results posted
    Enrollment 72→69
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Difference in time to program between the two arms at Programming VisitNow Change in Motor FunctionTime frame: at least four months post implant → Programming visit Day 1 after Randomization
    Interventions Arm changed Standard of Care Arm→Standard of Care Programming then Novel programming Arm; Novel Arm→Novel Programming then Standard of Care (SOC) programming Arm
    + 3 other changes: index terms, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03037398
Responsible party
Sponsor
First posted
Jan 31, 2017
Start date
Jan 11, 2017
Primary completion
Apr 2, 2025
Completion
Apr 2, 2025
Results posted
Oct 5, 2026
Last update
Oct 5, 2026

Study contacts

Natalie Bloom Lyons
study director · Boston Scientific Neuromodulation Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion